• Does DAA Therapy for HCV Infection Increase Survival in Patients Who Have Responded to Treatment for Hepatocellular Carcinoma?

Does DAA Therapy for HCV Infection Increase Survival in Patients Who Have Responded to Treatment for Hepatocellular Carcinoma?

In patients who have received successful treatment for HCV-related hepatocellular carcinoma (HCC), eradication of the HCV infection with direct-acting antiviral (DAA) significantly reduces risk of death, researchers report in the November issue of Gastroenterology. Chronic hepatitis C virus (HCV) infection is the most common cause of HCC in North America and Europe. DAA

Read more
  • Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Chronic infection with the hepatitis C virus (HCV) causes epigenetic changes in liver cells that alter gene expression patterns and continue to affect risk for hepatocellular carcinoma (HCC), regardless of patients’ response to direct-activating antiviral (DAA) agents, researchers report in the June issue of Gastroenterology. These alterations might be targeted

Read more
  • Review: How Does the Tumor Stroma Contribute to Pancreatic Cancer Progression, and Can We Stop It?

Review: How Does the Tumor Stroma Contribute to Pancreatic Cancer Progression, and Can We Stop It?

Recently developed approaches for reshaping the pancreatic tumor stroma might be used in treatments for pancreatic cancer, according to a review in the March issue of Gastroenterology. The authors discuss relationships among the pancreatic tumor extracellular matrix, the vasculature, the immune system, and metabolism, and how these might be manipulated to stop pancreatic tumor

Read more
  • How Could Lamins Protect Against Steatohepatitis?

How Could Lamins Protect Against Steatohepatitis?

Lamin A/C acts maintains hepatocyte nuclear shape and protects male mice from steatohepatitis by regulating growth hormone signaling and reducing activity of STAT1, researchers report in the November issue of Cellular and Molecular Gastroenterology and Hepatology. These observations show how variants in genes encoding lamins affect risk for steatohepatitis and liver fibrosis. Lamins are nuclear intermediate filament proteins that help form

Read more
  • What is the Best Management Strategy for Patients With NAFLD?

What is the Best Management Strategy for Patients With NAFLD?

Management of patients with non-alcoholic fatty liver disease (NAFLD) requires combined efforts of general practitioners, hepatologists, and other experts, Herbert Tilg explains in a Mentoring, Education, and Training Corner article in the August issue of Gastroenterology. NAFLD has become the most common liver disease worldwide. It ranges from simple steatosis in the absence

Read more
  • What are the Most Accurate Non-invasive Techniques for Measuring Liver Fibrosis and Steatosis?

What are the Most Accurate Non-invasive Techniques for Measuring Liver Fibrosis and Steatosis?

Magnetic resonance elastography (MRE) is more accurate than transient elastography (TE) in identifying liver fibrosis of stage 1 or more, researchers report in the February issue of Gastroenterology, using biopsy analysis as the standard. They also show that MRI-based proton density fat fraction (MRI-PDFF) analysis is more accurate than TE-based

Read more
  • Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Mice with defects in intestinal epithelial permeability develop more severe steatohepatitis when placed on a diet high in saturated fat, fructose, and cholesterol (HFCD) than control mice, and colon tissues from patients with non-alcoholic fatty liver disease (NAFLD) have similar defects in intestinal epithelial permeability, researchers report in the October

Read more
  • Can Blood Levels of Ammonia Predict Risk and Frequency of Hepatic Encephalopathy in Patients With Cirrhosis?

Can Blood Levels of Ammonia Predict Risk and Frequency of Hepatic Encephalopathy in Patients With Cirrhosis?

Fasting levels of ammonia (NH3) in blood identify patients at risk for complications of overt hepatic encephalopathy (HE), researchers report in the June issue of Clinical Gastroenterology and Hepatology. Patients with HE might benefit from NH3-lowering therapy. Humans have no repository for excess dietary nitrogen, so we convert excess dietary

Read more
  • What is the Best Treatment for Severe Alcoholic Hepatitis?

What is the Best Treatment for Severe Alcoholic Hepatitis?

Corticosteroids, alone or in combination with pentoxifylline or N-acetylcysteine (NAC), reduce short-term mortality in patients with severe alcoholic hepatitis, a meta-analysis shows in the October issue of Gastroenterology. However, there is no treatment to reduce medium-term mortality, the authors find. Severe alcoholic hepatitis is characterized by progressive inflammatory injury to hepatocytes and

Read more
  • Video: Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Video: Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Obeticholic acid significantly reduces biochemical features of primary biliary cirrhosis (PBC) in patients with an inadequate response to ursodeoxycholic acid (UDCA) therapy, Gideon M. Hirschfield et al report in the April issue of Gastroenterology. Hirschfield discusses the details of the study and its findings in a video abstract: PBC is a progressive, autoimmune

Read more